Biogen (BIIB) Stock Forecast & Price Target

Compare

4,979 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

12 Buy

10 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$182.94

▲(4.64% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $182.94 with a high forecast of $250.00 and a low forecast of $143.00. The average price target represents a 4.64% change from the last price of $174.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"$119","152":"$152","185":"$185","218":"$218","251":"$251"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":182.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$182.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$143.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,152,185,218,251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.78,183.3353846153846,188.89076923076922,194.44615384615383,200.00153846153847,205.55692307692308,211.1123076923077,216.6676923076923,222.22307692307692,227.77846153846156,233.33384615384614,238.88923076923078,244.4446153846154,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.78,178.1769230769231,178.57384615384615,178.97076923076924,179.3676923076923,179.76461538461538,180.16153846153847,180.55846153846153,180.95538461538462,181.3523076923077,181.74923076923076,182.14615384615385,182.5430769230769,{"y":182.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.78,175.10461538461539,172.42923076923077,169.75384615384615,167.07846153846154,164.40307692307692,161.7276923076923,159.0523076923077,156.37692307692308,153.70153846153846,151.02615384615385,148.35076923076923,145.67538461538462,{"y":143,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":164.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$250.00

Average Price Target$182.94

Lowest Price Target$143.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Abrahams

RBC Capital

$210

Buy

20.12%

Upside

Reiterated

12/18/25

RBC says post points to Biogen expanding into BTK degrader spaceRBC says post points to Biogen expanding into BTK degrader space

Paul Matteis

Stifel Nicolaus

$202

Buy

15.55%

Upside

Reiterated

12/15/25

Stifel Nicolaus Sticks to Its Buy Rating for Biogen (BIIB)

Terence Flynn

Morgan Stanley

$149→$156

Hold

-10.77%

Downside

Reiterated

12/12/25

Biogen price target raised to $156 from $149 at Morgan StanleyBiogen price target raised to $156 from $149 at Morgan Stanley

Mohit Bansal

Wells Fargo

$190

Hold

8.68%

Upside

Reiterated

12/10/25

Wells Fargo Sticks to Its Hold Rating for Biogen (BIIB)

Morten Herholdt

HSBC

$144→$143

Sell

-18.20%

Downside

Downgraded

12/10/25

Biogen downgraded to Reduce from Hold at HSBCBiogen downgraded to Reduce from Hold at HSBC

Myles Minter

William Blair

Buy

―

Reiterated

12/09/25

Biogen's Strategic Growth and Innovative Edge Justify Buy Rating

Andrew Fein

H.C. Wainwright

$194

Buy

10.97%

Upside

Reiterated

12/03/25

H.C. Wainwright Remains a Buy on Biogen (BIIB)

Sumant Kulkarni

Canaccord Genuity

$220

Buy

25.84%

Upside

Reiterated

12/01/25

Biogen (BIIB) Gets a Buy from Canaccord Genuity

Salveen Richter

Goldman Sachs

$197

Buy

12.69%

Upside

Reiterated

11/24/25

Biogen's Strategic Advantage: Buy Rating Amid Competitive Shifts and Promising Pipeline Developments

David Amsellem

Piper Sandler

$118→$157

Hold

-10.19%

Downside

Reiterated

11/21/25

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Biogen (NASDAQ: BIIB) and Alpha Tau Medical Ltd (NASDAQ: DRTS)

Tim Anderson

Bank of America Securities

$167

Hold

-4.47%

Downside

Reiterated

11/03/25

Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB)

Evan Seigerman

BMO Capital

$128→$150

Hold

-14.20%

Downside

Reiterated

11/03/25

Biogen (BIIB) Receives a Hold from BMO Capital

William Pickering

Bernstein

$155→$157

Hold

-10.19%

Downside

Reiterated

11/03/25

Biogen price target raised to $157 from $155 at BernsteinBiogen price target raised to $157 from $155 at Bernstein

Thomas Shrader

BTIG

Hold

―

Reiterated

11/03/25

Biogen's Hold Rating: Balancing Promising Growth with Revenue Challenges and Infrastructure Development

Salim Syed

Mizuho Securities

$169→$177

Buy

1.25%

Upside

Reiterated

11/03/25

Biogen (BIIB) Receives a Buy from Mizuho Securities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Abrahams

RBC Capital

$210

Buy

20.12%

Upside

Reiterated

12/18/25

RBC says post points to Biogen expanding into BTK degrader spaceRBC says post points to Biogen expanding into BTK degrader space

Paul Matteis

Stifel Nicolaus

$202

Buy

15.55%

Upside

Reiterated

12/15/25

Stifel Nicolaus Sticks to Its Buy Rating for Biogen (BIIB)

Terence Flynn

Morgan Stanley

$149→$156

Hold

-10.77%

Downside

Reiterated

12/12/25

Biogen price target raised to $156 from $149 at Morgan StanleyBiogen price target raised to $156 from $149 at Morgan Stanley

Mohit Bansal

Wells Fargo

$190

Hold

8.68%

Upside

Reiterated

12/10/25

Wells Fargo Sticks to Its Hold Rating for Biogen (BIIB)

Morten Herholdt

HSBC

$144→$143

Sell

-18.20%

Downside

Downgraded

12/10/25

Biogen downgraded to Reduce from Hold at HSBCBiogen downgraded to Reduce from Hold at HSBC

Myles Minter

William Blair

Buy

―

Reiterated

12/09/25

Biogen's Strategic Growth and Innovative Edge Justify Buy Rating

Andrew Fein

H.C. Wainwright

$194

Buy

10.97%

Upside

Reiterated

12/03/25

H.C. Wainwright Remains a Buy on Biogen (BIIB)

Sumant Kulkarni

Canaccord Genuity

$220

Buy

25.84%

Upside

Reiterated

12/01/25

Biogen (BIIB) Gets a Buy from Canaccord Genuity

Salveen Richter

Goldman Sachs

$197

Buy

12.69%

Upside

Reiterated

11/24/25

Biogen's Strategic Advantage: Buy Rating Amid Competitive Shifts and Promising Pipeline Developments

David Amsellem

Piper Sandler

$118→$157

Hold

-10.19%

Downside

Reiterated

11/21/25

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Biogen (NASDAQ: BIIB) and Alpha Tau Medical Ltd (NASDAQ: DRTS)

Tim Anderson

Bank of America Securities

$167

Hold

-4.47%

Downside

Reiterated

11/03/25

Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB)

Evan Seigerman

BMO Capital

$128→$150

Hold

-14.20%

Downside

Reiterated

11/03/25

Biogen (BIIB) Receives a Hold from BMO Capital

William Pickering

Bernstein

$155→$157

Hold

-10.19%

Downside

Reiterated

11/03/25

Biogen price target raised to $157 from $155 at BernsteinBiogen price target raised to $157 from $155 at Bernstein

Thomas Shrader

BTIG

Hold

―

Reiterated

11/03/25

Biogen's Hold Rating: Balancing Promising Growth with Revenue Challenges and Infrastructure Development

Salim Syed

Mizuho Securities

$169→$177

Buy

1.25%

Upside

Reiterated

11/03/25

Biogen (BIIB) Receives a Buy from Mizuho Securities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

1 Month

xxx

Success Rate

12/21 ratings generated profit

Average Return

+1.92%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +1.92% per trade.

3 Months

xxx

Success Rate

19/36 ratings generated profit

Average Return

+0.58%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.78% of your transactions generating a profit, with an average return of +0.58% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

16/35 ratings generated profit

Average Return

-0.49%

reiterated a buy rating 3 months ago

Copying Marc Goodman's trades and holding each position for 1 Year would result in 45.71% of your transactions generating a profit, with an average return of -0.49% per trade.

2 Years

xxx

Success Rate

14/35 ratings generated profit

Average Return

-10.23%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -10.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 24 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 182.94.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $1.74 with a range of $1.30 to $3.90. The previous quarter’s EPS was $4.81. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.21B with a range of $2.10B to $2.50B. The previous quarter’s sales results were $2.45B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 182.94.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 4.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy which is based on 12 buy ratings, 10 hold ratings and 1 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is 182.94. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $250.00 ,the lowest forecast is $143.00. The average price target represents 4.64% Increase from the current price of $174.82.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Detailed List of Analyst Forecasts